(Reuters) – The U.S. Food and Drug Administration (FDA) approved GSK’s combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
(Reporting by Sneha S K, Mariam Sunny and Mrinmay Dey in Bengaluru; Editing by Alan Barona and Stephen Coates)
